Acadia Pharmaceuticals ACAD Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $282.21M+58.8% | $177.7M-31.1% | $258M+1.7% | $253.64M+16.5% | $217.7M-31.9% | ||
| $569.25M-11.3% | $641.99M+9.0% | $589.02M+15.9% | $508.36M+9.6% | $463.88M+6.3% | ||
| $135.35M+11.4% | $121.46M+4.8% | $115.85M+7.8% | $107.51M+1.7% | $105.74M+7.1% | ||
| -$78K-102% | $4.89M— | $0-100% | $4.1M-60.8% | $10.45M+136% | ||
| $1.1B+3.2% | $1.06B-1.3% | $1.08B+12.1% | $960.55M+10.3% | $870.94M-7.2% | ||
| $14.65M+95.1% | $7.51M+103% | $3.71M+4.5% | $3.55M+1.4% | $3.5M-17.0% | ||
| $106.17M-2.5% | $108.89M-2.4% | $111.62M-2.4% | $114.34M-2.3% | $117.06M-2.3% | ||
| $1.61B+2.6% | $1.56B+17.5% | $1.33B+8.6% | $1.23B+8.2% | $1.13B-4.7% | ||
| $305.52M+10.3% | $277.11M-22.3% | $356.58M+8.0% | $330.02M+9.1% | $302.53M-23.4% | ||
| $357.16M+6.0% | $336.81M-18.5% | $413.5M+2.6% | $403.17M+9.8% | $367.13M-19.3% | ||
| $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | ||
| -$1.81B+0.2% | -$1.81B+13.1% | -$2.09B+3.3% | -$2.16B+1.2% | -$2.19B+0.9% | ||
| $1.25B+1.7% | $1.23B+33.8% | $917.27M+11.5% | $822.38M+7.5% | $765.24M+4.4% | ||
| $1.61B+2.6% | $1.56B+17.5% | $1.33B+8.6% | $1.23B+8.2% | $1.13B-4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Acadia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.59 — current assets exceed current liabilities.
- Where does Acadia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.